Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-02-19
DOI
https://doi.org/10.3324/haematol.2025.300144
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial

Meng‐Yao Lu, Karen Sinclair, Alphan Küpesiz, Yogi Chopra et al.
Haematologica
Hematopoietic Stem Cell Transplantation
article

Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial

Meng‐Yao Lu, Karen Sinclair, Alphan Küpesiz, Yogi Chopra, T Güngör, Federica Locatelli, Ho Joon Im, Maria Gabriela Matos, Séverine Peyrard, Tommaso Stefanelli, Yvonne S. Smith, Cristina Díaz-de-Heredia, Bulent Antmen, Sunil Bhat, Hyoung Jin Kang, Yoshiyuki Takahashi, Katsuyoshi Koh
article en

Abstract

No abstract available for this paper.
Haematologica
Novartis (Switzerland) (CH), Akdeniz University (TR), Hospital for Sick Children (CA), Asan Medical Center (KR), Narayana Health (IN), University of Ulsan (KR), Novartis (France) (FR), Support group for adolescents and children with cancer (BR), Saitama Children's Medical Center (JP), Vall d'Hebron Institut de Recerca (ES), Seoul National University Children's Hospital (KR), Akdeniz University Hospital (TR), Bambino Gesù Children's Hospital (IT), Vall d'Hebron Hospital Universitari (ES), University Children's Hospital Zurich (CH), National Taiwan University Hospital (TW), Novartis (Ireland) (IE), Adana Science and Technology University (TR), Nagoya University (JP)
Novartis Pharmaceuticals Corporation, Novartis Pharma, Novartis Pharmaceuticals UK Limited
Openalex Percentile: Top 48%
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial — Meng‐Yao Lu, Karen Sinclair, et al. · Haematologica (2026) | TGRS Research Map | TGRS